

June 30, 2020

RBM-007 Phase I Trial for Achondroplasia Registered in Clinical Trial Database

TOKYO, June 30, 2019 - RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TSE-Mothers: 4591, President and CEO: Yoshikazu Nakamura, Ph.D.) today announced that the outline of Phase I study of RBM-007 (anti-FGF2 aptamer) for treatment of Achondroplasia has been registered and published in JapicCTI (※) .

<https://www.clinicaltrials.jp/cti-user/trial/ShowDirect.jsp?directLink=0p52SZqEULFxxBQ0QuD.Vg-->

Contacts for inquiries or additional information:

RIBOMIC Inc.

Corporate Planning Department

ir.inquiry@ribomic.com

※ JapicCTI (Japic Clinical Trials Information) is accredited as a primary registry in the WHO Registry Network and operated by the Japan Pharmaceutical Information Center (JAPIC).